Treatment of severe acute necrotizing encephalopathy of childhood with interleukin-6 receptor blockade in the first 24 h as add-on immunotherapy shows favorable long-term outcome at 2 years.
Patrick H HosieCarylyn LimTimothy R D ScottMichael CardamoneMichelle A FarrarCatherine FrithPeter I AndrewsJason PinnerSekhar PillaiPublished in: Brain & development (2023)
The very early use of interleukin-6 blockade as 'add-on' immunotherapy in the first 24 h demonstrates potential for improving the long-term outcome in patients classified as high-risk using the ANE-SS.